Exploring Legal Frameworks for the Clinical Use of Psychedelic Substances in Mental Health Treatment
Abstract
In recent years, interest in the use of psychedelic substances in the treatment of mental disorders has increased significantly. Recent research shows the potential of psychedelic substances such as psilocybin, LSD, and MDMA to treat disorders such as major depression, post-traumatic stress disorder (PTSD), and substance addiction. However, the clinical use of psychedelic substances remains very limited due to significant legal obstacles. This study aims to explore the relevant legal framework for the clinical use of psychedelic substances in the treatment of mental disorders. By considering various rules and regulations at national and international levels, we explore the challenges and opportunities in creating an enabling legal framework for the clinical use of psychedelic substances. Our analysis highlights differences in legal approaches between countries, with some countries such as the United States beginning to pave the way for research and clinical use of psychedelic substances in mental treatment, while other countries still maintain a strict approach to the use of psychedelic substances. The results of this study provide important insights for policymakers, health practitioners, and researchers to understand the existing legal framework and challenges faced in integrating psychedelic substances into clinical practice. Thus, this study may help guide the development of policies that promote safe and responsible access to psychedelic therapy in the treatment of mental disorders.
Keywords
Full Text:
PDFReferences
Argento, Elena, Shira Goldenberg, Kathleen Deering, Jennifer Lavalley, Melissa Braschel, Brittany Bingham, and others, ‘Interest in Receiving Psychedelic-Assisted Therapy among Marginalized Women: Implications and Findings from a Community-Based Study in Canada’, Drug and Alcohol Dependence Reports, 3.March (2022), 100044
Dimensions, Ethical, ‘Ethical Limbo and Enhanced Informed Consent in Psychedelic-Assisted Therapy’, 2023
Gattuso, James J., Daniel Perkins, Simon Ruffell, Andrew J. Lawrence, Daniel Hoyer, Laura H. Jacobson, and others, ‘Default Mode Network Modulation by Psychedelics: A Systematic Review’, International Journal of Neuropsychopharmacology, 26.3 (2023), 155–88
Jacobs, Edward, ‘Transformative Experience and Informed Consent to Psychedelic-Assisted Psychotherapy’, Frontiers in Psychology, 14 (2023)
Kelly, John R., Claire M. Gillan, Jack Prenderville, Clare Kelly, Andrew Harkin, Gerard Clarke, and others, ‘Psychedelic Therapy’s Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective’, Frontiers in Psychiatry, 12.December (2021)
van der Kolk, Bessel A., Julie B. Wang, Rachel Yehuda, Leah Bedrosian, Allison R. Coker, Charlotte Harrison, and others, ‘Effects of MDMA-Assisted Therapy for PTSD on Self-Experience’, PloS One, 19.1 (2024), e0295926
Kotoula, Vasileia, Jennifer W. Evans, Claire E. Punturieri, and Carlos A. Zarate, ‘Review: The Use of Functional Magnetic Resonance Imaging (FMRI) in Clinical Trials and Experimental Research Studies for Depression’, Frontiers in Neuroimaging, 2 (2023)
Lampe, Joanna R., ‘The Controlled Substances Act (CSA): A Legal Overview for the 116th Congress’,
Key Congressional Reports for October 2019. Part II, 2020, 287–333
Lande, Adolf, ‘The Single Convention on Narcotic Drugs, 1961’, International Organization, 16.4 (1962), 776–97
‘Medicinal Use of Medicinal Use Of’
Pilecki, Brian, Jason B. Luoma, Geoff J. Bathje, Joseph Rhea, and Vilmarie Fraguada Narloch, ‘Ethical
and Legal Issues in Psychedelic Harm Reduction and Integration Therapy’, Harm Reduction Journal, 18.1 (2021), 1–14
Populations, Thermal variation and factors influencing vertical migration behavior in Daphnia, and PhD Daniel Harris, BA, Lynn McNicoll, MD, Gary Epstein-Lubow, MD, and Kali S. Thomas, ‘乳鼠心肌提取 HHS Public Access’, Physiology & Behavior, 176.1 (2017), 139–48
‘Recent Developments Involving Psychedelics’, 2023, 125–38
Review, Clark L A W, ‘Beyond Cannabis’, 2019, 851–92
Reynolds, Charles F., ‘Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression - Quo Vadis?’, JAMA Psychiatry, 78.5 (2021), 476–78
Transform Drug Policy Foundation, ‘How to Regulate Psychedelics A Practical Guide’, 2023
Yaden, David B., Brian D. Earp, and Roland R. Griffiths, ‘Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care’, Cambridge Quarterly of Healthcare Ethics, 31.4 (2022), 464– 71
Yaden, David B., Matthew W. Johnson, Roland R. Griffiths, Manoj K. Doss, Albert Garcia-Romeu, Sandeep Nayak, and others, ‘Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities’, International Journal of Neuropsychopharmacology, 24.8 (2021), 615–23
Zhang, Gongliang, and Robert W. Stackman, ‘The Role of Serotonin 5-HT2A Receptors in Memory and Cognition’, Frontiers in Pharmacology, 6.OCT (2015), 1–17
Ziff, Shawn, Benjamin Stern, Gregory Lewis, Maliha Majeed, and Vasavi Rakesh Gorantla, ‘Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review’, Cureus, 14.2 (2022), 1–12
DOI: http://dx.doi.org/10.56444/ulrev.v8i2.5241
Article Metrics
Abstract view : 42 timesPDF - 0 times
Refbacks
- There are currently no refbacks.
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
View |